In-silico identification of frequently mutated genes and their co-enriched metabolic pathways associated with Prostate cancer progression

被引:1
作者
Singh, Anshika N. [1 ]
Sharma, Neeti [1 ]
机构
[1] Ajeenkya DY Patil Univ ADYPU, Sch Engn, Charholi Budruk, Pune 412105, India
关键词
bioinformatics; hub genes; mutation; Prostate cancer; TP53; AMINO-ACID VARIANTS; MUTATIONS; PROTEIN; EXPRESSION; PROGNOSIS; DATABASE;
D O I
10.1111/and.14236
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Prostate cancer (PCa) has emerged as a significant health burden in men globally. Several genetic anomalies such as mutations and also epigenetic aberrations are responsible for the heterogeneity of this disease. This study identified the 20 most frequently mutated genes reported in PCa based on literature and database survey. Further gene ontology and functional enrichment analysis were conducted to determine their co-modulated molecular and biological pathways. A protein-protein interaction network was used for the identification of hub genes. These hub genes identified were then subjected to survival analysis. The prognostic values of these identified genes were investigated using GEPIA and HPA. Gene Ontology analysis of the identified genes depicted that these genes significantly contributed to the cell cycle, apoptosis, angiogenesis and TGF-beta receptor signalling. Further, the research showed that high expressions of identified mutated genes led to a reduction in the long-term survival of PCa patients, which was supported by immunohistochemical and mRNA expression level data. Our results suggest that identified panel of mutated genes viz., CTNNB1, TP53, ATM, AR and KMT2D play crucial roles in the onset and progression of PCa, thereby providing candidate diagnostic markers for PCa for individualised treatment in the future.
引用
收藏
页数:11
相关论文
共 52 条
  • [1] In silico learning of tumor evolution through mutational time series
    Auslander, Noam
    Wolf, Yuri I.
    Koonin, Eugene V.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (19) : 9501 - 9510
  • [2] In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer
    Baruah, Meghna M.
    Sharma, Neeti
    [J]. MEDICAL ONCOLOGY, 2019, 36 (05)
  • [3] Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer
    Carter, H. Ballentine
    Helfand, Brian
    Mamawala, Mufaddal
    Wu, Yishuo
    Landis, Patricia
    Yu, Hongjie
    Wiley, Kathleen
    Na, Rong
    Shi, Zhuqing
    Petkewicz, Jacqueline
    Shah, Sameep
    Fantus, Richard J.
    Novakovic, Kristian
    Brendler, Charles B.
    Zheng, S. Lilly
    Isaacs, William B.
    Xu, Jianfeng
    [J]. EUROPEAN UROLOGY, 2019, 75 (05) : 743 - 749
  • [4] UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
    Chandrashekar, Darshan S.
    Bashel, Bhuwan
    Balasubramanya, Sai Akshaya Hodigere
    Creighton, Chad J.
    Ponce-Rodriguez, Israel
    Chakravarthi, Balabhadrapatruni V. S. K.
    Varambally, Sooryanarayana
    [J]. NEOPLASIA, 2017, 19 (08): : 649 - 658
  • [5] Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO
  • [6] 2-W
  • [7] ATM Mutations in Cancer: Therapeutic Implications
    Choi, Michael
    Kipps, Thomas
    Kurzrock, Razelle
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1781 - 1791
  • [8] ATM signalling and cancer
    Cremona, C. A.
    Behrens, A.
    [J]. ONCOGENE, 2014, 33 (26) : 3351 - 3360
  • [9] Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI [10.1093/nar/gkt1102, 10.1093/nar/gkz1031]
  • [10] Prevalent mutations in prostate cancer
    Dong, JT
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 97 (03) : 433 - 447